Mode
Text Size
Log in / Sign up

Exploratory analysis of RYGB and SG shows variable LDL cholesterol response in patients with obesity and high LDL cholesterolTwo bariatric surgeries lower cholesterol through completely different biological paths

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note variable LDL response after SG versus consistent reduction after RYGB in patients with obesity and high LDL cholesterol.

This exploratory analysis of a randomized clinical trial (BASALTO) included 30 patients with obesity and high LDL cholesterol. The population was divided into 15 patients receiving Roux-en-Y gastric bypass (RYGB) and 15 patients receiving sleeve gastrectomy (SG). Follow-up assessments occurred at 3 months and 12 months. The primary outcome measured LDL cholesterol response, while secondary outcomes included lipidomic changes, cholesterol absorption patterns, and specific molecular levels.

Results indicated consistent reductions in LDL cholesterol after RYGB, though absolute numbers and effect sizes were not reported. In contrast, LDL cholesterol response after SG demonstrated marked interindividual variability. No significant associations were observed between lipidomic changes and LDL cholesterol after RYGB. However, after SG, monoacylglycerol (16:0, 20:4, 18:1) changes were directly associated with LDL cholesterol at 3 months. Additionally, cholestanol increases were directly associated with LDL cholesterol at 12 months with a pFDR of 0.039, and HexCer 18:0 increases were directly associated with LDL cholesterol at 12 months with a pFDR of 0.031.

Safety and tolerability data, including adverse events, serious adverse events, discontinuations, and specific tolerability metrics, were not reported. The study was limited by its exploratory nature and the lack of significant associations observed after RYGB. The practice relevance suggests that LDL cholesterol reduction after RYGB appears independent of shifts in selected lipids, whereas variability after SG may be partly driven by cholesterol absorption and ceramide-related pathways.

Clinicians should interpret these findings with caution given the exploratory analysis designation. The observed associations after SG indicate potential pathways involving cholesterol absorption and ceramide-related molecules. Further research is needed to confirm these mechanisms and establish definitive causal links before altering clinical management based solely on these preliminary findings.

Imagine standing in a doctor's office with a bag of chips in your hand. You are worried about your weight and your heart health. You have heard about two main surgeries that can help you lose weight. One is called Roux-en-Y gastric bypass. The other is sleeve gastrectomy. Both surgeries help people lose a lot of weight. But what happens to your cholesterol after the operation?

High LDL cholesterol is a major risk for heart disease. Many people take statins to lower these bad fats in their blood. Some patients want to avoid pills if surgery can fix the problem. Doctors have noticed that not everyone gets the same result from these operations. Some patients see huge drops in cholesterol. Others see little change at all.

Why does this happen? The answer lies in how your body handles fats. Your body uses complex chemicals called lipids to store and move energy. These lipids act like tiny messengers inside your cells. When you eat, your body absorbs fats from food. This process changes the levels of different lipids in your blood.

But here is the twist. The two surgeries change these lipid messengers in very different ways. One surgery seems to ignore these specific chemical shifts. The other surgery relies heavily on them. Understanding this difference could help doctors pick the best option for you.

The First Surgery Ignores Lipid Shifts

The Roux-en-Y gastric bypass works by rerouting your small intestine. Food goes from your stomach directly to a lower part of your intestine. This limits how much food you can eat and how much you absorb.

Researchers studied thirty patients who had this surgery. They took blood samples before the operation and three months after. They also took samples twelve months after the surgery. They looked at more than fifty different types of lipids.

The results were surprising. At twelve months, this surgery consistently lowered LDL cholesterol. However, the changes in lipid levels did not match the drop in cholesterol. The surgery lowered cholesterol without needing specific shifts in these chemical messengers. It seems the physical rerouting of the gut does the heavy lifting here.

The Second Surgery Needs Chemical Help

Sleeve gastrectomy is different. It removes part of your stomach to make it smaller. You feel full faster and eat less. But the path of your food stays mostly the same.

When researchers looked at patients with this surgery, they saw a different story. Some patients had great results. Others did not see much improvement in their cholesterol levels. The results varied a lot from person to person.

The study found specific chemical changes linked to success. At three months, changes in monoacylglycerols mattered. These are fats that help your body absorb nutrients. At twelve months, increases in cholestanol and HexCer 18:0 were key. These changes were directly linked to how much LDL cholesterol dropped.

This doesn't mean this treatment is available yet. The science is still being sorted out. But the pattern is clear. For sleeve gastrectomy, the way your body absorbs cholesterol plays a big role.

Why The Difference Matters

Think of your body like a factory. The Roux-en-Y surgery changes the factory layout. It stops raw materials from entering the main line. This naturally lowers the output of bad cholesterol.

The sleeve gastrectomy is more like adjusting the machines inside the factory. It changes how the machines work. Sometimes the machines run better. Sometimes they do not. The specific chemical signals tell you which machine is running well.

This distinction is vital for patient care. If a patient has high cholesterol, a doctor might choose the bypass surgery. It offers a more predictable result for heart health. If a patient needs the sleeve, the doctor must monitor their lipid levels closely.

You might wonder if this changes your decision. It depends on your goals. If lowering cholesterol is a top priority, the bypass surgery looks more reliable. It works consistently across many patients.

If you are considering the sleeve, talk to your doctor about your risk factors. Your body chemistry matters. Some people naturally absorb cholesterol differently. This surgery might work well for you. For others, it might not lower cholesterol as expected.

Doctors will look at your full health picture. They will consider your weight, your heart risk, and your lifestyle. This new research adds one more piece to the puzzle. It helps them make a smarter choice for your specific biology.

This study was small. It only looked at thirty patients. Scientists need to check these findings in larger groups. They want to see if these patterns hold true for everyone.

More research is coming. We will learn more about how these surgeries affect your heart. This knowledge will help doctors guide patients better. It will also help patients understand what to expect.

The goal is simple. We want to keep your heart healthy while you lose weight. Understanding these biological differences brings us closer to that goal. It turns a complex medical mystery into a clear path forward.

Study Details

Study typeRct
Sample sizen = 30
EvidenceLevel 2
Follow-up3.0 mo
PublishedMay 2026
View Original Abstract ↓
BACKGROUND AND AIMS: The Bariatric Surgery and LDL Cholesterol (BASALTO) randomized clinical trial reported differential LDL cholesterol responses after Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG). In this exploratory analysis of BASALTO we characterized lipidomic changes associated with both procedures and their relationship with LDL cholesterol response. METHODS AND RESULTS: Plasma samples of 30 patients with obesity and high LDL cholesterol (15 RYGB, 15 SG) were analyzed using targeted mass spectrometry to quantify over 50 pre-defined lipid species at baseline, 3 months, and 12 months after surgery. At 12 months, RYGB induced consistent reductions in LDL cholesterol, whereas SG showed marked interindividual variability. Both procedures were associated with shared and procedure-specific lipidomic changes, including divergent patterns in cholesterol absorption. No significant associations between lipidomic changes and LDL cholesterol were observed after RYGB. In contrast, after SG, changes in monoacylglycerols (16:0, 20:4, 18:1) at 3 months and increases in cholestanol (pFDR = 0.039) and HexCer 18:0 (pFDR = 0.031) at 12 months were directly associated with LDL cholesterol response. CONCLUSION: LDL cholesterol reduction after RYGB appears independent of shifts in selected lipids, whereas variability after SG may be partly driven by cholesterol absorption and ceramide-related pathways. CLINICAL TRIAL REGISTRATION: NCT03975478.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.